Moleculin Biotech Inc (MBRX) Actualités

Form 8-K - Current report

Form 8-K - Current report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 8-K - Current report

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...